Purpose: To evaluate the changes of outer retinal tubulations (ORTs) as seen on spectral-domain optical coherence tomography (SD OCT) in eyes with neovascular age-related macular degeneration (AMD) where treatment was switched from intravitreal ranibizumab to intravitreal aflibercept.
Methods: This was a prospective study of eyes diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept, conducted at a single centre (Department of Ophthalmology at Pitié Salpetriere Hospital, Paris VI University) from January to July 2015. Before and after treatment was switched from ranibizumab to aflibercept, SD-OCT was used to evaluate the presence of ORTs. Additional assessments in this patient group included best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA). Changes in pigment epithelium detachments (PED), presence of intraretinal cysts, and presence of subretinal fluid (SRF) were also noted.
Results: Twenty-four eyes of 24 consecutive patients (15 female/nine male, mean age 70 years) diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept were included in the analysis. After receiving aflibercept, patients were followed for a mean of 6.1 months. Prior to treatment switch, 97 % of eyes showed ORTs, while after treatment switch to aflibercept, at the end of the study period, 75 % had ORTs (p = 0.219). Changes in BCVA (LogMAR) were not statistically significant (1.16 ± 0.44 to 1.18 ± 1.06, p = 0.12), however, a significant reduction in central macular thickness (CMT) (from 406 μm ± 112 to 263 μm ± 68, p = 0.001), PED (from 70.8 % to 41.7 % , p = 0.016), presence of intraretinal cysts (from 83.3 % to 33.3 %, p = 0.002) and SRF (from 91.7 % to 25 %, p = 0.001 ) were noted.
Conclusion: After switching from ranibizumab treatment to aflibercept, ORTs remained present in 75 % of eyes, and significant reductions in CMT, PED, and SRF, and presence of intraretinal cysts were observed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00417-016-3423-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis.
Am J Ophthalmol
December 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada. Electronic address:
Purpose: To assess the risk of renal adverse events, particularly acute kidney injury (AKI), between intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Design: Meta-analysis.
Methods: A systematic literature search was conducted on Ovid Medline, Embase and the Cochrane Library for randomized controlled trials (RCTs) published from January 2005 to February 2024 involving adult patients receiving anti-VEGF intravitreal injections for agerelated macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion.
Multifocal Torpedo Maculopathy Complicated by Choroidal Neovascularization.
J Vitreoretin Dis
December 2024
Associated Retinal Consultants, Royal Oak, MI, USA.
To present a pediatric patient with a unique configuration of torpedo maculopathy complicated by macular choroidal neovascularization (CNV). A single case was retrospectively reviewed. An 8-year-old male child presented with decreased vision in the left eye and was found to have 2 distinct torpedo maculopathy lesions, 1 a smaller hypopigmented lesion in the temporal parafovea and the other a larger hyperpigmented comet-shaped lesion in the temporal periphery.
View Article and Find Full Text PDFTopographical Quantification of Hyper-Reflective Foci May Predict the Development of Macular Atrophy in Patients With Neovascular Age-Related Macular Degeneration.
Invest Ophthalmol Vis Sci
December 2024
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro," Bari, Italy.
Purpose: The purpose of this study was o examine the optical coherence tomographic (OCT) characteristics of hyper-reflective foci (HRF) in patients with neovascular age-related macular degeneration (nAMD) and to assess the potential of HRF as a predictive factor for the development of macular atrophy following anti-vascular endothelial growth factor (anti-VEGF) therapy.
Methods: This was a retrospective analysis of 61 treatment-naïve eyes diagnosed with exudative AMD and type 1 macular neovascularization (MNV). The HRF was identified in the inner retina and outer retina layers, and the treatment response of HRF was documented.
Comparison of intravitreal anti-VEGF agents and oral carbonic anhydrase inhibitors in the treatment of cystoid macular edema secondary to retinitis pigmentosa.
Front Pharmacol
December 2024
Shenzhen Eye Hospital, Shenzhen Eye Institute, Shenzhen, Guangdong, China.
Purpose: To compare the efficacy of intravitreal antivascular endothelial growth factor (anti-VEGF) agents with oral carbonic anhydrase inhibitors (CAIs) in treating cystoid macular edema (CME) secondary to retinitis pigmentosa (RP).
Methods: This retrospective study analyzed 98 patients (98 eyes) with RP-CME: 47 (48.0%) received intravitreal anti-VEGF agents (Ranibizumab or Bevacizumab) and 51 (52.
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema.
BMC Ophthalmol
December 2024
Genentech, Inc, South San Francisco, CA, USA.
Background: Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compared for eyes with DME that did and did not receive such initial doses.
Methods: This was a retrospective database study using American Academy of Ophthalmology Intelligent Research in Sight Registry data (01/01/15-31/12/20; index period).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!